Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa

Carvalho, 2006, Characterization of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-beta-lactamase in a hospital located in Rio de Janeiro, Brazil, Microb. Drug. Resist., 12, 103, 10.1089/mdr.2006.12.103 Clinical and Laboratory Standards Institute, 2007 El Amin, 2005, Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates, APMIS, 113, 187, 10.1111/j.1600-0463.2005.apm1130306.x Gales, 2002, Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997–2000), Diagn. Microbiol. Infect. Dis., 44, 301, 10.1016/S0732-8893(02)00499-6 Gaynes, 2005, Overview of nosocomial infections caused by gram-negative bacilli, Clin. Infect. Dis., 41, 848, 10.1086/432803 Landman, 2002, Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned, Arch. Intern. Med., 162, 1515, 10.1001/archinte.162.13.1515 Lauretti, 1999, Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate, Antimicrob. Agents Chemother., 43, 1584, 10.1128/AAC.43.7.1584 Livermore, 2002, Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?, Clin. Infect. Dis., 34, 634, 10.1086/338782 Lolans, 2005, First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States, Antimicrob. Agents Chemother., 49, 3538, 10.1128/AAC.49.8.3538-3540.2005 Lomovskaya, 2001, Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy, Antimicrob. Agents Chemother., 45, 105, 10.1128/AAC.45.1.105-116.2001 Masuda, 2000, Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 44, 3322, 10.1128/AAC.44.12.3322-3327.2000 Middlemiss, 2004, Differential impact of MexB mutations on substrate selectivity of the MexAB-OprM multidrug efflux pump of Pseudomonas aeruginosa, J. Bacteriol., 186, 1258, 10.1128/JB.186.5.1258-1269.2004 Pai, 2001, Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates, Antimicrob. Agents Chemother., 45, 480, 10.1128/AAC.45.2.480-484.2001 Patzer, 2004, Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998–2001), J. Antimicrob. Chemother., 53, 451, 10.1093/jac/dkh095 Poirel, 2000, Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France, Antimicrob. Agents Chemother., 44, 891, 10.1128/AAC.44.4.891-897.2000 Quale, 2006, Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates, Antimicrob. Agents Chemother., 50, 1633, 10.1128/AAC.50.5.1633-1641.2006 Quinn, 1991, Imipenem resistance in Pseudomonas aeruginosa PAO: mapping of the OprD2 gene, Antimicrob. Agents Chemother., 35, 753, 10.1128/AAC.35.4.753 Saeed, 2006, Interinstitutional and intrainstitutional transmission of a strain of Acinetobacter baumannii detected by molecular analysis: comparison of pulsed-field gel electrophoresis and repetitive sequence-based polymerase chain reaction, Infect. Control. Hosp. Epidemiol., 27, 981, 10.1086/507286 Srikumar, 2000, Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa, J. Bacteriol., 182, 1410, 10.1128/JB.182.5.1410-1414.2000 Syrmis, 2004, Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element–based PCR assays, J. Med. Microbiol., 53, 1089, 10.1099/jmm.0.45611-0 Tam, 2005, Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa, Diagn. Microbiol. Infect. Dis., 52, 145, 10.1016/j.diagmicrobio.2005.02.010 Tam, 2005, Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 49, 4920, 10.1128/AAC.49.12.4920-4927.2005 Tam, 2007, Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa, Clin. Microbiol. Infect., 13, 413, 10.1111/j.1469-0691.2006.01674.x Vidal, 1996, Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes, Arch. Intern. Med., 156, 2121, 10.1001/archinte.156.18.2121